NUS1
NUS1, also known as NgBR, TANGO14 and C6orf68, is a subunit of the dehydrodolichyl diphosphate synthase complex, which supports dolichol synthesis and protein glycosylation in the endoplasmic reticulum. It also acts as a specific receptor for the N-terminus of Nogo-B. Browse Assay Genie's current range of NUS1 research reagents below, or read on for the biology behind the target.
NUS1 pairs with DHDDS to form the dehydrodolichyl diphosphate synthase (DDS) complex, an essential part of the dolichol monophosphate (Dol-P) biosynthetic machinery. Both subunits contribute to enzymatic activity, condensing multiple copies of isopentenyl pyrophosphate (IPP) onto farnesyl pyrophosphate (FPP) to produce dehydrodolichyl diphosphate (Dedol-PP). This is a precursor of dolichol phosphate, the sugar carrier used in protein glycosylation in the endoplasmic reticulum. The complex synthesises long-chain polyprenols, mostly of C95 and C100 chain length. NUS1 also regulates the glycosylation and stability of nascent NPC2, which promotes trafficking of LDL-derived cholesterol, and it acts as a specific receptor for the N-terminus of Nogo-B, a neural and cardiovascular regulator.
The NUS1 gene encodes a type I single transmembrane domain receptor that is a subunit of cis-prenyltransferase. The protein belongs to the UPP synthase family and localises to the endoplasmic reticulum membrane. The mouse ortholog is Nus1, and knockout of the orthologous gene in mice causes embryonic lethality before day 6.5. Pseudogenes of the human gene have been defined on chromosomes 13 and X.
The gene was previously named chromosome 6 open reading frame 68 and nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae). Naturally occurring mutations in NUS1 cause a congenital disorder of glycosylation and are associated with epilepsy. NUS1 is highly expressed in non-small cell lung carcinomas and in oestrogen receptor-alpha positive breast cancer cells, where it promotes epithelial mesenchymal transition, and it is associated with poor prognosis in patients with hepatocellular carcinoma.
NUS1 is essential for dolichol synthesis, and dolichol phosphate serves as the sugar carrier for protein glycosylation in the endoplasmic reticulum.
Naturally occurring NUS1 mutations cause a congenital disorder of glycosylation and are associated with epilepsy.
NUS1 is highly expressed in non-small cell lung carcinoma and ER-alpha positive breast cancer cells, and is linked to poor prognosis in hepatocellular carcinoma.
NUS1 regulates NPC2 glycosylation and stability, supporting LDL-derived cholesterol trafficking, and serves as the receptor for Nogo-B.
NUS1 forms the dehydrodolichyl diphosphate synthase complex with DHDDS. Both subunits contribute to producing dehydrodolichyl diphosphate, a precursor of dolichol phosphate used as a sugar carrier in ER protein glycosylation. NUS1 also regulates NPC2 glycosylation and stability and acts as the receptor for Nogo-B.
NUS1 is also called NgBR, TANGO14, MGC7199 and C6orf68. Earlier names were chromosome 6 open reading frame 68 and nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. cerevisiae). The NgBR alias reflects its role as the Nogo-B receptor. Check the datasheet of any product for its validated reactivity.
Yes. Naturally occurring NUS1 mutations cause a congenital disorder of glycosylation and are associated with epilepsy. High expression is reported in non-small cell lung carcinoma and ER-alpha positive breast cancer, and it is associated with poor prognosis in hepatocellular carcinoma. Mouse Nus1 knockout is embryonic lethal.
Related targets and proteins connected to NUS1 biology with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q96E22; product specifications from Assay Genie datasheets.